What Solarea Bio does

Solarea Bio, Inc. (also operating as Sōlaria Biō and formerly known as Journa Health) is a privately held Delaware-incorporated biotechnology company headquartered in Waltham, Massachusetts, that develops microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. Its core product, Bōndia™, is an FDA-classified medical food formulated as a synbiotic — combining four proprietary plant-sourced probiotic strains (Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Lactiplantibacillus plantarum SBS04260, and the yeast Pichia kudriavzevii SBS04263) with prebiotic fibers (organic blueberry powder and oligofructose from chicory root) and algae-derived Vitamin D3 — delivered via a precision-release capsule designed to survive gastric acid and reach the gut alive. The product targets the gut–bone axis in postmenopausal and osteopenic women, with a peer-reviewed 286-woman 12-month double-blind RCT published in Osteoporosis International (2025) reporting an 85% reduction in femoral neck bone loss, a 73.7% reduction in hip bone loss in women with BMI ≥30, and a 78.9% reduction in severe GI symptoms.

The company generates revenue through a hybrid direct-to-consumer and B2B2C model. Bōndia is sold primarily through the company's Shopify-hosted e-commerce storefront (solaria.bio) via subscription tiers priced from $83/month (annual plan, $999/year) up to $125/month for one-time purchases, with a 30-day money-back guarantee and HSA/FSA eligibility. A practitioner affiliate program channels healthcare-provider recommendations through unique referral links, complemented by a DexaFit partnership bundling DEXA bone-density screening with product subscriptions. The company has raised approximately $36M+ in disclosed equity capital across a 2018 seed round, a 2020 Series A (~$11.2M), a 2023 Series B first close of $15M led by S2G Ventures (targeting up to $25M), and additional SEC exempt-offering filings of $1M (2024) and $9.91M (2025), supplemented by a $3M NIH/National Institute on Aging grant. Management is led by CEO Catherine Balsam-Schwaber (appointed October 2025), with co-founder Eric Schott, PhD as COO and scientific leadership under VP of R&D Mark Charbonneau, PhD; the company employs 11–50 people and is preparing to launch Arthrīva, a second synbiotic medical food for rheumatoid arthritis, in Spring 2026.

Name

Solarea Bio

Legal name

Sōlaria Biō, Inc.

Website

https://solareabio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Solarea Bio is a privately held biotechnology company that develops FDA-classified synbiotic medical foods from plant-sourced microbes; it sells Bōndia, a clinically validated bone-health product, via DTC subscription and a practitioner affiliate channel to postmenopausal and osteopenic women in the United States.

Ownership category

akta.pro rank

Product category

Medical Foods / Synbiotic Supplements

NAICS

Fruit and Vegetable Canning, Pickling, and Drying (31142)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium) (AFAKAJAD)

Keywords

• Medical foods
• Synbiotic supplements
• Bone health products
• Microbial therapeutics
• Gut-bone axis

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Direct-to-Consumer Product Sales: Primary revenue stream from selling Bōndia synbiotic medical food directly to consumers through the company's e-commerce website. Products available as one-time purchases or subscription plans with recurring billing. Subscription model provides predictable recurring revenue with discounts for longer commitments.
2. One-Time Product Purchases: Single-month supply purchases available for consumers who prefer not to commit to subscriptions. Priced at $125/month for one-time buyers.
3. Practitioner Affiliate Referrals: Healthcare providers earn commissions when they refer patients who purchase Bōndia through their unique affiliate link or code. Practitioners can apply to join the program and receive sample products to aid recommendations.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Solarea Bio develops and sells FDA-regulated microbial medical foods. Its flagship product Bōndia is a plant-sourced synbiotic combining four proprietary probiotic strains with prebiotic fibers and algae-derived Vitamin D3, clinically proven to reduce bone loss in postmenopausal women via the gut-bone axis. The company sells direct-to-consumer via its website and through a practitioner affiliate channel.

Product overview

Solarea Bio (formerly Journa Health) is a biotechnology company offering a portfolio of microbial-based medical foods derived from beneficial microbes found in fruits and vegetables. The core product is Bōndia™, a plant-sourced synbiotic medical food clinically proven to reduce bone loss by targeting the gut-bone axis. The company is also developing Arthrīva, a product for rheumatoid arthritis expected in Spring 2026. Bōndia is positioned as a medical food (held to higher FDA safety and efficacy standards) rather than a dietary supplement, and is available via direct-to-consumer subscription through the company's Shopify-hosted website.

Differentiator

Problem solved

Functional benefit

Products and services

• Bōndia™ A plant-sourced, living synbiotic medical food designed to reduce bone loss in postmenopausal women by targeting the gut-bone axis. Contains four proprietary probiotic strains (Lactiplantibacillus plantarum SBS04260, Levilactobacillus brevis SBS04254, Leuconostoc mesenteroides SBS04255, Pichia kudriavzevii SBS04263) combined with prebiotic fibers from blueberry, chicory root, and algae-derived Vitamin D3. Sold as a medical food (FDA-regulated, higher standard than supplements) via direct-to-consumer subscription.

Quantifiable outcome

• 85% reduction in femoral neck bone loss in women with osteopenia after 12 months of consistent use
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Harvard Medical SchoolflagshipStrategic or Co-development PartnerOngoing research partnership referenced in company materials. Clinical trial results and ongoing Harvard Medical School partnership reflect the company's commitment to uncompromising science and clinical validation.
• DexaFitcoreStrategic or Co-development PartnerPartnership for bone density screening services. Offers bundled bone health packages combining DexaFit DEXA scans with Sōlaria Bio product subscriptions. Free DEXA scans included with product subscriptions at select locations.
• Parsley HealthminorGTM or Marketing PartnerWellness healthcare provider featured as partner logo on website. Dr. Robin Berzin, Parsley Health founder, has spoken publicly about her personal osteopenia diagnosis and recommends Bōndia.
• Aligned Modern HealthminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this wellness healthcare provider.
• Wondr HealthminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this digital health platform.
• Goal DailyminorGTM or Marketing PartnerPartner logo displayed on company website, indicating a marketing or referral relationship with this wellness brand.
• mindbodygreenminorGTM or Marketing PartnerWellness media brand featured as partner logo on website, suggesting content marketing or referral partnership.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Pendulum Therapeutics: Pendulum sells clinically validated, multi-strain synbiotic products via DTC subscription targeting specific conditions (e.g., metabolic health, glucose control). Closely comparable to Solarea Bio on proprietary probiotic strains, clinical evidence-based marketing, and direct subscription model.
• Seed Health: Seed Health develops proprietary synbiotic formulations with patented strains and sells via DTC subscription. Comparable on proprietary-strain IP, science-forward branding, and subscription GTM, though Seed targets gut microbiome health more broadly than Solarea's indication-specific positioning.
• Metagenics: Metagenics is a practitioner-channel medical food and supplement manufacturer with a strong focus on bone health, gut health, and inflammation. Closely comparable to Solarea Bio on FDA medical food positioning, practitioner/affiliate distribution model, and condition-specific functional foods.
• Microbiome Labs: Microbiome Labs distributes practitioner-channel probiotic and microbiome products, including clinically studied formulations like Megasporebiotic. Comparable to Solarea Bio on practitioner/affiliate GTM and science-driven probiotic formulations.
• Designs for Health: Designs for Health is a practitioner-channel supplement brand offering condition-specific protocols (including bone, gut, and inflammation). Comparable to Solarea Bio on practitioner affiliate distribution and clinician-focused selling motion.
• Pure Encapsulations: Pure Encapsulations is a practitioner-grade supplement brand owned by Nestlé Health Science, sold through healthcare professionals with condition-specific lines. Comparable to Solarea Bio on practitioner-only distribution and hypoallergenic, science-led positioning.
• Standard Process: Standard Process is a practitioner-channel whole-food supplement and medical food manufacturer. Comparable to Solarea Bio on practitioner distribution, condition-specific products, and medical food regulatory positioning.

Broad incumbents

• Thorne: Thorne is a broad-line supplement brand sold through practitioners and DTC with strong clinical/athlete positioning. Comparable as a wider portfolio competitor in the practitioner-channel supplement market, though less indication-specific than Solarea Bio's medical food focus.
• Nestlé Health Science: Nestlé Health Science is a global medical nutrition incumbent offering medical foods across bone, digestive, and metabolic health (e.g., Peptamen, Resource, Optifast). Comparable as a broad medical-foods incumbent against which Solarea competes for category share and physician mind-share.
• Novonesis: Novonesis (formerly Chr. Hansen) is a global probiotic and enzyme ingredient manufacturer with deep microbial strain IP. Comparable as a broader ingredient/probiotic incumbent that controls much of the upstream strain supply Solarea Bio relies upon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/SolariaBio
• Instagraminstagram.com/solaria.bio
• LinkedInlinkedin.com/company/solareabioinc
• Xtwitter.com/solaria_bio
• YouTubeyoutube.com/@SolariaBio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solarea Bio